Enter at least 3 characters
HOME > Products > schnupfen endrine ® drops 0,1 %, spray 0,1 %
 

schnupfen endrine ® drops 0,1 %, spray 0,1 %

active ingredient: Xylometazolinhydrochlorid

schnupfen endrine® drops 0.1 %

schnupfen endrine® spray 0.1 %



Active ingredient: Xylometazoline hydrochloride


Therapeutic Indication: For short-term therapy in swellings (congestion) of the mucous membrane of the nose. schnupfen endrine® drops 0.1 % and schnupfen endrine spray 0.1 % are intended for use in children from the age of 6 years and in adults.



PZN 03925069: schnupfen endrine® drops 0.1 % (N1, 10 ml)

PZN 03925052: schnupfen endrine® spray 0.1 % (N1, 10 ml)

 

Summary of product characteristics (schnupfen endrine® drops 0.1 %, schnupfen endrine® spray 0.1 %)

  • Suitable for children of age 6 years and above

  • Xylometazoline has a vaso-constrictive effect and reduces swelling of the mucous membranes. The onset of action usually occurs within 5 to 10 minutes.



schnupfen endrine®. Active ingredient: Xylometazoline hydrochloride. Pharmacologically active substance: schnupfen endrine® drops 0.1 %: 1 ml of nasal drops contains: Xylometazoline hydrochloride 1.0 mg. schnupfen endrine® spray 0.1 %:  1 ml nasal spray/1 puff with 90 microlitres contains: Xylometazoline hydrochloride 1.0 mg/0.09mg. Other constituents: schnupfen endrine® drops 0.1 %: Benzalkonium chloride, purified water, hypromellose, sodium chloride, macrogolglycerol hydroxystearate (Ph. Eur.), disodium hydrogen phosphate, sodium dihydrogen phosphate, eucalyptus oil, laevo-menthol. schnupfen endrine® spray 0.1 %: Benzalkonium chloride, purified water, sodium chloride, macrogolglycerol hydroxystearate (Ph. Eur.), disodium hydrogen phosphate, sodium dihydrogen phosphate, eucalyptus oil, laevo-menthol.Therapeutic indication: For short-term therapy in congestion of the mucous membranes of the nose. Intended for adults and schoolchildren. Contraindications: Allergic reaction to xylometazoline hydrochloride, eucalyptus oil, laevo-menthol or one of the other constituents of schnupfen endrine® drops/spray 0.1 %. Certain form of a chronic rhinitis (Rhinitis sicca). Condition following surgical removal of the pituitary gland through the nose or other surgical operations that expose the cerebral membrane. Children under 6 years of age. Patients with bronchial asthma or other respiratory diseases accompanied by pronounced hypersensitivity of the air passages. Side effects: Burning and dryness of the nasal mucous membrane, sneezing. Increased sensation of a “blocked” nose after the effect has worn off, nose bleeds, hypersensitive reactions (skin rash, itching, swelling of skin and mucous membrane), heart palpitations, accelerated cardiac action (tachycardia), hypertension, cardiac arrhythmia, restlessness, insomnia, fatigue (drowsiness, sedation), headache, hallucinations (primarily in children), cramps (especially in children). In correspondingly sensitized patients, hypersensitivity reactions (including shortness of breath) may be triggered by laevo-menthol and eucalyptus oil. Inhalation of schnupfen endrine® drops/spray 0.1 % may lead to bronchoconstriction. Warnings: Contains benzalkonium chloride, laevo-menthol and eucalyptus oil. Observe the enclosed patient information leaflet. Pharmacy medicine. Valid as of: September 2015. Chiesi GmbH, Hamburg, Germany

Service

-